BridgeBio Pharma vs HUTCHMED (China)
HUTCHMED (China) reported revenue of $548 million in fiscal 2025, about the same as BridgeBio Pharma's $502 million in fiscal 2025. BridgeBio Pharma's revenue grew 126.3% in its latest year, and HUTCHMED (China)'s fell 13.0%. BridgeBio Pharma had an operating margin of -104.2%, against -7.1% at HUTCHMED (China). Free cash flow was −$447 million at BridgeBio Pharma and −$79 million at HUTCHMED (China).
Side by side
| BridgeBio Pharma | HUTCHMED (China) | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $502M | $548M |
| Revenue growth | 126.3% | −13.0% |
| Revenue growth a year, last 5 years | 127.7% | 19.2% |
| Gross margin | 95.8% | 38.7% |
| Operating margin | −104.2% | −7.1% |
| Net margin | −146.0% | 83.3% |
| Free cash flow | −$447M | −$79M |
| Free cash flow margin | −89.0% | −14.4% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $48M | $0M |
| Change in diluted share count | 2.9% | 0.0% |
| Last close | $78.18 | $13.45 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | sold $86.2 million | — |
| Piotroski F-score | 3 of 9 | 4 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
BridgeBio PharmaHUTCHMED (China)
Operating margin
Percent of revenue
BridgeBio PharmaHUTCHMED (China)
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
BridgeBio PharmaHUTCHMED (China)
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the BridgeBio Pharma and HUTCHMED (China) pages.